Clinical trials: Alcohol Withdrawal
Alcohol Withdrawal
Prazosin for Alcohol Use Disorder With Withdrawal Symptoms
This is a Phase 2 single site randomized clinical trial (RCT) to be supported by a new NIH-NIAAA grant, R01-AA029113-01, to assess the efficacy of Prazosin (16mg/day) versus Placebo over a 12 week treatment period, followed by a…
- Trial name
- NCT04793685
- Testing
- Prazosin, 12-Step Facilitation with Relapse Prevention and Contingency Management
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Yale University
Alcohol Withdrawal Syndrome
MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA)
This study examine the efficacy of oral magnesium supplementation as an adjuvant therapy for decreasing intensity of alcohol withdrawal symptoms among inpatients requiring pharmacological treatment of their AWS.
- Trial name
- MAGMA (NCT03033823)
- Testing
- Magnesium
- Where
- 11 sites in France
- Volunteers
- 105 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alcohol Withdrawal
Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal
A randomized, double-blind controlled trial comparing treatment outcomes between chlordiazepoxide, or gabapentin to treat alcohol withdrawal syndrome in alcohol dependent veteran subjects.
- Trial name
- NCT01573052
- Testing
- Chlordiazepoxide, Gabapentin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- VA Salt Lake City Health Care System
Alcoholic Cirrhosis, Alcohol Abstinence
Safety & Efficacy of Baclofen for Alcohol Withdrawal in Chronic Liver Disease With Active Alcohol Consumption
This study examines the safety and effectiveness of baclofen as a treatment for alcohol withdrawal in patients with chronic liver disease who continue drinking.
- Conditions
- Alcoholic Cirrhosis, Alcohol Abstinence, Alcohol Withdrawal, Medication Toxicity
- Trial name
- BAWIC (NCT06840652)
- Testing
- Baclofen
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Corporacion Parc Tauli
Alcohol Dependence
Brain Derived Neurotrophic Factor Serum Levels Evolution During the Six Months After Alcohol Withdrawal
Alcohol dependence is accompanied by several neurological mechanisms involving neuronal plasticity and neoneurogenesis, requiring Brain Derived Neurotrophic factor (BDNF) synthesis.
- Trial name
- NCT01491347
- Where
- 4 sites in France
- Volunteers
- 389 people
- Sponsor
- Centre Hospitalier Esquirol
Alcohol Withdrawal
Metabolism of Chlordiazepoxide in the Treatment of Alcohol Withdrawal Symptoms
The aim of this study is to elucidate if CYP-phenotypes, variations in CYP-genotypes and dose of chlordiazepoxide is correlated to chlordiazepoxide plasma concentrations in patients admitted to Intensive Care or High Dependency…
- Trial name
- NCT05563350
- Testing
- Blood samples
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Alcoholism
Comparing Gabapentin and Lorazepam for Treating Alcohol Withdrawal
This study will evaluate a safe and useful medication for outpatient detoxification that is as effective as benzodiazepines in the short-term, and more effective in the protracted withdrawal period.
- Trial name
- NCT00011297
- Testing
- gabapentin (Neurontin), lorazepam (Ativan)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Intoxication, Delirium Tremens (DTs)
Preventox - a Digital Intervention for Patients With Intoxications in Intensive Care
Background and purpose At present, occasional referral to psychiatric or addiction services is the only aftercare option offered following an intoxication/overdose requiring intensive care.
- Conditions
- Intoxication, Delirium Tremens (DTs), Poisoning by Psychoactive Substances, Suicidal Attempt
- Trial name
- NCT07819500
- Testing
- Preventox, a digital self-help tool for patients with intoxications in intensive care., Preventox control group
- Volunteers
- 50 people
- Sponsor
- Karolinska Institutet
Alcohol Use Disorder
Non-invasive Vagal Nerve Stimulation as Novel Treatment to Improve Functional Outcomes in Veterans With Alcohol Use Disorder
Alcohol use disorder (AUD) is a major health concern amongst Veterans as it causes functional impairments and decreased quality of life.
- Trial name
- NCT06399653
- Testing
- Cervical transcutaneous vagus nerve stimulation (active comparator)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- VA Office of Research and Development
Alcohol Dependence, Alcohol Withdrawal Syndrome
Assessment of Valproate on Ethanol Withdrawal
Alcohol use disorder, or heavy drinking, is commonly seen in patients who present to trauma centers. These patients are at risk for Alcohol Withdrawal Syndrome (AWS), which is collection of symptoms that can range from anxiety…
- Conditions
- Alcohol Dependence, Alcohol Withdrawal Syndrome, Trauma, Heavy Drinking
- Trial name
- PAVE (NCT03235531)
- Testing
- Valproate, Lorazepam
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- CAMC Health System
Alcohol Withdrawal, Lactic Acidosis
Alcohol: Thiamine and or Magnesium 1
Patients who suffer Alcohol Use Disorder (AUD) have a 30-80% incidence of thiamine deficiency causing Wernicke's Encephalopathy (WE).
- Conditions
- Alcohol Withdrawal, Lactic Acidosis, Vitamin B1 Deficiency, Magnesium Deficiency
- Trial name
- AToM1 (NCT03466528)
- Testing
- Magnesium Sulfate, Pabrinex
- Where
- United Kingdom
- Volunteers
- 127 people
- Sponsor
- Glasgow Royal Infirmary
Alcohol Withdrawal, Alcohol Dependence
Cannabidiol (CBD) for the Treatment of Alcohol Withdrawal
This study will explore the effectiveness and tolerability of Cannabidiol (CBD) in the treatment of alcohol withdrawal symptoms in an inpatient setting, in a double-blind randomised placebo-controlled trial.
- Trial name
- NCT04205682
- Testing
- Cannabidiol
- Where
- 2 sites in Australia
- Volunteers
- 52 people
- Sponsor
- South West Sydney Local Health District
Alcohol-related Liver Disease, Alcohol Dependence
Impact of COVID-19 Outbreak on the Alcohol Consumption in Patients With Alcohol-related Liver Disease (ICoLD)
The lockdown consequent to Coronavirus outbreak has had a differential impact on the drinking behaviour on the general population.
- Conditions
- Alcohol-related Liver Disease, Alcohol Dependence, Alcohol Withdrawal, Addiction, Alcohol
- Trial name
- NCT04876443
- Testing
- Study questionnaire
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- King's College Hospital NHS Trust
Alcohol Withdrawal Syndrome
Effect of Clinical and Biochemical Variables Over Morbidity and Mortality in Alcohol Withdrawal Syndrome Patients
The goal of this observational study is to describe the impact measured through the Odds Ratio (OR) of different variables of clinical and biochemical alterations on the duration of the syndrome alcohol withdrawal patients…
- Trial name
- NCT06589973
- Testing
- Study Cohort
- Where
- Mexico
- Volunteers
- 195 people
- Sponsor
- Hospital General de Mexico
Alcohol Use Disorder (AUD), Withdrawal From Addictive Substance; Detoxification
Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving
Cannabidiol (CBD), one of the most prevalent cannabinoids in cannabis (marijuana) has been shown to reduce alcohol withdrawal symptoms in laboratory animals.
- Conditions
- Alcohol Use Disorder (AUD), Withdrawal From Addictive Substance; Detoxification, Craving
- Trial name
- NCT07148843
- Testing
- Cannabidiol (CBD)
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Johns Hopkins University
Alcohol Withdrawal, Nutrition Disorders
Riboflavin for Glutamate Reduction in Alcohol Withdrawal
This RCT intends to investigate the use of oral Riboflavin (Vitamin B2) for reduction of blood glutamate levels in the setting of acute alcohol withdrawal.
- Conditions
- Alcohol Withdrawal, Nutrition Disorders, Alcohol Use Disorder
- Trial name
- RGRAW (NCT04232800)
- Testing
- Riboflavin
- Volunteers
- 40 people
- Sponsor
- Oregon Health and Science University
Alcohol Withdrawal, Psychophysiologic Reaction
Auricular Vagal Stimulation in Alcohol Craving
Background: The cause of the vegetative symptoms is a sympathetic driven misbalance of the autonomous nervous system. To restore vegetative balance in alcohol withdrawal syndrome new neuro-modulatory methods, such as percutaneous…
- Trial name
- VNS_CRAV (NCT05131334)
- Testing
- auriStim, for auricular vagal stimulation
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Medical University of Vienna
Substance Withdrawal Syndrome
Process Evaluation Standardised Nurse-led Approach for Risk Screening and Decrease of Alcohol Withdrawal in ENT
In ear, nose, throat (ENT) and jaw surgery departments, up to 60% of patients suffer from alcohol dependence (Allen et al., 2009), and may develop an alcohol withdrawal syndrome (AWS) when undergoing sur-gery.
- Trial name
- NCT02782156
- Testing
- Process evaluation
- Where
- Switzerland
- Volunteers
- 89 people
- Sponsor
- University Hospital, Basel, Switzerland
Acute Alcohol Withdrawal
Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal
This study is designed to evaluate dexmedetomidine as adjunctive therapy of severe alcohol withdrawal of medical ICU patients. Specifically, this study will assess whether adjunctive dexmedetomidine reduces the doses of…
- Trial name
- DATA (NCT00936377)
- Testing
- Dexmedetomidine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Colorado, Denver
Alcohol Withdrawal Syndrome
Preventing Alcohol Withdrawal Syndrome With Oral Baclofen
Adult medical/surgical inpatient hospital care is more difficult and more expensive when complicated by alcohol dependency (AD), especially for patients who develop alcohol withdrawal syndrome (AWS).
- Trial name
- NCT02052440
- Testing
- Baclofen
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Denver Health and Hospital Authority